{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:32:43Z","timestamp":1792146763354,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s12032-012-0190-3","type":"journal-article","created":{"date-parts":[[2012,2,29]],"date-time":"2012-02-29T11:21:47Z","timestamp":1330514507000},"page":"2379-2384","source":"Crossref","is-referenced-by-count":10,"title":["The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis"],"prefix":"10.1007","volume":"29","author":[{"given":"Grzegorz","family":"Helbig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Wieczorkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wo\u017aniczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wi\u015bniewska-Pi\u0105ty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rusek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomira","family":"Kyrcz-Krzemie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,1]]},"reference":[{"key":"190_CR1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF(PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31:737\u201340.","journal-title":"Leuk Res"},{"key":"190_CR2","first-page":"13","volume":"88","author":"F Passamonti","year":"2003","unstructured":"Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88:13\u20138.","journal-title":"Haematologica"},{"key":"190_CR3","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","volume":"118","author":"F Cervantes","year":"2002","unstructured":"Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118:786\u201390.","journal-title":"Br J Haematol"},{"key":"190_CR4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.seminoncol.2005.04.011","volume":"32","author":"F Cervantes","year":"2005","unstructured":"Cervantes F, Barosi G. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging. Semin Oncol. 2005;32:395\u2013402.","journal-title":"Semin Oncol"},{"key":"190_CR5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","volume":"88","author":"B Dupriez","year":"1996","unstructured":"Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013\u20138.","journal-title":"Blood"},{"key":"190_CR6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"190_CR7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","volume":"131","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Lasho TL, Schwager SM, et al. The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005;131:320\u20138.","journal-title":"Br J Haematol"},{"key":"190_CR8","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","volume":"107","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107:2098\u2013100.","journal-title":"Blood"},{"key":"190_CR9","doi-asserted-by":"crossref","unstructured":"Pearson TC, Messinezy M, Westwood N, et al. A Polycythemia vera updated: diagnosis, pathobiology, and treatment. Hematology (Am Soc Hematol Educ Program): 2000; 51\u201368.","DOI":"10.1182\/asheducation-2000.1.51"},{"key":"190_CR10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"190_CR11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00277-005-0042-8","volume":"85","author":"J Thiele","year":"2006","unstructured":"Thiele J, Kvasnicka M. Grade of bone marrow fibrosis is associated with relevant hematological findings: a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006;85:226\u201332.","journal-title":"Ann Hematol"},{"key":"190_CR12","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood"},{"key":"190_CR13","volume-title":"ISCN","author":"F Mitelman","year":"1995","unstructured":"Mitelman F. ISCN. An International System for Human Cytogenetic Nomenclature. Basel: Karger; 1995."},{"key":"190_CR14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"190_CR15","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","volume":"110","author":"G Barosi","year":"2007","unstructured":"Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110:4030\u20136.","journal-title":"Blood"},{"key":"190_CR16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22:756\u201361.","journal-title":"Leukemia"},{"key":"190_CR17","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","volume":"114","author":"P Guglielmelli","year":"2009","unstructured":"Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009;114:1477\u201383.","journal-title":"Blood"},{"key":"190_CR18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","volume":"25","author":"A Tefferi","year":"2010","unstructured":"Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival. Leukemia. 2010;25:105\u20139.","journal-title":"Leukemia"},{"key":"190_CR19","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/leu.2010.126","volume":"24","author":"P Guglielmelli","year":"2010","unstructured":"Guglielmelli P, Biamonte F, Spolverini A, et al. Frequency and clinical correlates of JAK2 46\/1 (GGCC) haplotype in primary myelofibrosis. Leukemia. 2010;24:1533\u20137.","journal-title":"Leukemia"},{"key":"190_CR20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3324\/haematol.13721","volume":"94","author":"P Guglielmelli","year":"2009","unstructured":"Guglielmelli P, Barosi G, Pieri L, et al. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica. 2009;94:144\u20136.","journal-title":"Haematologica"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-012-0190-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-012-0190-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-012-0190-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T12:23:18Z","timestamp":1593778998000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-012-0190-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,1]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["190"],"URL":"https:\/\/doi.org\/10.1007\/s12032-012-0190-3","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,1]]}}}